Application note: See what’s really in your formulation with backgrounded membrane imaging
Backgrounded Membrane Imaging (BMI), used by the HORIZON® particle analysis system, performs measurements of subvisible protein aggregates.
List view / Grid view
Backgrounded Membrane Imaging (BMI), used by the HORIZON® particle analysis system, performs measurements of subvisible protein aggregates.
Read how Cyto-Mine® has helped improve overall efficiency and productivity in cell line development at FUJIFILM Diosynth Biotechnologies.
Hybridoma-based antibody discovery: the challenges and how to overcome them using microfluidic picodroplet technology.
A study in Finland has found a strong connection between the A143T variant of the GLA gene and increased risk of Fabry cardiomyopathy, which affects the heart, kidneys and nervous system.
In vitro evaluation of hepatic function using a primary human hepatocyte 3D spheroid culture system
Hypoxia measurements in live and fixed cells using fluorescence microscopy and high-content imaging
A new technology developed by scientists combines small molecule screening methods with machine learning algorithms to identify novel antibiotics that inhibit ribosomes.
A Frost & Sullivan award has been given to a new label-free single-cell analysis and sorting platform for utilising cutting-edge technologies.
Are you missing the bigger picture with your AAV analytics? Subvisible particle analysis should not require millilitres of precious sample.
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
Scientists have produced hundreds of organoids which they say could be produced on a large-scale as a low-cost tissue model to help research and test new medulloblastoma therapies.
A high-throughput screening test of different cannabinoids has demonstrated that CBC and CBG exhibit anti-tumour effects.
Modelling technique that simultaneously evaluates the effects of possible protein mutations on protein-protein interactions implicated in disease, could cut pre-drug screening time, says research.
Researchers have screened thousands of existing drug molecules against cancer cell lines to discover almost 50 compounds that combat the condition.
Researchers have developed a novel metal-based fragment library of molecules that can be used to screen for new drug candidates.